Managed Access Agreement for Spinraza – Biogen Update

A Managed Access Agreement (MAA) for Spinraza has been confirmed as currently in discussion by the manufacturer, Biogen. The MAA for Spinraza is being explored by Biogen, NHS England and NICE (National Institute for Health and Care Excellence), whilst the longer term funding of the treatment is considered under the Single Technology Appraisal (STA) process, by NICE.

The Agreement could give more people with SMA access to the life-changing treatment while further data and evidence are gathered over several years as to the drugs efficacy and case for longer term funding, should the STA process not support the treatments funding. Next steps are detailed in a Biogen community update



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.